Icatibant peptide is a synthetic, highly selective bradykinin B₂ receptor antagonist. Its amino acid sequence exhibits high homology with endogenous bradykinin. It functions by competitively binding to the active site of B₂ receptors on the surface of target cells, thereby blocking bradykinin's binding. Notably, after binding, it does not activate the downstream G protein-coupled signaling pathway. Consequently, it inhibits the biological effects mediated by bradykinin, such as vasodilation, increased vascular permeability, and the release of inflammatory mediators. Ultimately, this mechanism blocks the cascade of inflammatory pathways driven by bradykinin.
As a highly selective bradykinin B₂ receptor antagonist, it can specifically target and bind to B₂ receptors on the surface of target cells (such as vascular endothelial cells and smooth muscle cells), competitively antagonizing the binding process of endogenous bradykinin to its receptors. Since the drug lacks agonistic activity after binding to the B₂ receptor, it cannot initiate subsequent inflammation-related signal transduction, thereby effectively blocking the bradykinin-mediated excessive inflammatory response pathway. This makes it an important therapeutic agent for diseases characterized by abnormal activation of the bradykinin pathway, such as hereditary angioedema.
Our Products Form
Icatibant COA
Icatibant blocks bradykinin mediated inflammatory response
Icatibant peptide is a synthetically designed peptide receptor antagonist. Its molecular structure is specifically modified, and its amino acid sequence exhibits high homology with endogenous bradykinin, specifically D-Arg-Arg-Pro-Hyp-Gly-Thi-Ser-D-Tic-Oic-Arg. This structural homology endows it with a spatial conformation similar to bradykinin, enabling it to precisely fit the active binding site of the bradykinin B₂ receptor. This is the core structural basis for its competitive antagonism. Compared to natural bradykinin, Icatibant, after artificial modification, demonstrates significantly enhanced molecular stability, making it less susceptible to rapid degradation by endogenous peptidases. This allows it to maintain effective concentrations in the body for an extended period, thereby exerting sustained antagonistic effects.
Its core molecular action logic is not to directly disrupt the structure of the B₂ receptor, but rather to occupy the receptor's active binding site through competitive binding. This process blocks the binding of endogenous bradykinin to the receptor and inhibits the subsequent bradykinin-mediated inflammatory signal transduction.
(II)High Specificity and Targeting of Receptor Binding
It exhibits a high degree of binding specificity towards bradykinin receptors. It primarily targets and acts on the B₂ receptor, while showing no significant binding activity to the B₁ receptor, another important receptor in the bradykinin family. Consequently, it does not interfere with physiological functions mediated by the B₁ receptor.
From the perspective of molecular affinity, Icatibant's binding constant to the B₂ receptor is significantly lower than that of endogenous bradykinin. This indicates its binding capacity to the B₂ receptor is far superior to that of bradykinin. Even in situations where endogenous bradykinin concentrations are elevated, it can preferentially bind to the B₂ receptor, effectively occupying its active sites.
Furthermore, B₂ receptors are widely distributed on the surface of various target cells involved in inflammatory responses, such as vascular endothelial cells, smooth muscle cells, and immune cells. Icatibant can specifically recognize and bind to these B₂ receptors on target cell surfaces without exerting nonspecific effects on irrelevant cells. This further enhances its targeting precision and reduces potential interference from nonspecific actions.
(III)Specific Blockade of Downstream Signaling Pathways
After endogenous bradykinin binds to the B₂ receptor, it triggers a conformational change in the receptor, subsequently activating downstream G protein-coupled signaling pathways. Specifically, this activation involves key signaling molecules such as phospholipase C (PLC) and adenylate cyclase (AC).
Upon activation, PLC promotes the generation of inositol trisphosphate (IP3) and diacylglycerol (DAG). IP3 can induce the release of calcium ions from intracellular stores, while DAG activates protein kinase C (PKC), thereby mediating inflammation-related biological effects such as the release of inflammatory mediators and changes in vascular permeability. When AC is activated, it regulates intracellular cyclic adenosine monophosphate (cAMP) concentration, affecting the activation and proliferation of immune cells and amplifying the inflammatory cascade.
Unlike bradykinin, when this drug binds to the B₂ receptor, it merely occupies the receptor's active site without inducing the conformational change required to trigger signal transduction.
Consequently, it fails to activate the downstream G protein-coupled signaling pathways or key signaling molecules like PLC and AC. This results in the complete blockade of the downstream inflammation-related signaling cascade, thereby inhibiting the bradykinin-mediated inflammatory cascade at its source and preventing further progression and amplification of the inflammatory response.
The binding of it to the B₂ receptor is non-covalent, primarily relying on intermolecular forces such as hydrogen bonds and hydrophobic interactions. This type of binding is characterized by rapid reversibility.
As icatibant peptide is gradually metabolized and cleared from the body, its bond with the B₂ receptor dissociates. Once dissociated, the B₂ receptor quickly reverts to its native conformation, regaining its ability to bind endogenous bradykinin and restoring normal physiological regulatory functions. From a pharmacokinetic perspective, this is primarily excreted through the kidneys, has a short half-life in the body, and is rapidly cleared, preventing long-term accumulation.
This rapid and reversible mode of action not only ensures the timeliness of icatibant's effect, allowing for quick blockade of inflammation-related signaling, but more importantly, it avoids prolonged interference with the body's normal physiological regulatory functions. After drug metabolism, the body can swiftly restore normal physiological functions mediated by the bradykinin B₂ receptor, such as vascular tone regulation and local immune defense. This significantly enhances the safety profile of the drug and reduces the risk of adverse effects, such as physiological dysfunction, that may arise from long-term use.
Exploration of Icatibant in Rheumatoid Arthritis
Rheumatoid Arthritis (RA), as a common chronic autoimmune inflammatory disease in clinical practice, is characterized by a prolonged and recurrent course. Its long-term progression can lead to joint deformity and functional loss, severely impacting patients' quality of life. The core pathological features of this disease are closely related to the abnormal activation of the bradykinin pathway. Clinical exploration of it in this context centers precisely on this core mechanism and can be specifically divided into the following aspects:
Based on the pathological features of abnormal bradykinin pathway activation in RA, Icatibant, leveraging its highly selective B₂ receptor antagonistic effect, has emerged as a potential therapeutic agent for this disease. Its core mechanism of action closely aligns with its molecular properties and the pathological mechanisms of RA. As a synthetically designed peptide antagonist, it shares a highly homologous molecular conformation with bradykinin. This allows it to preferentially bind to B₂ receptors on the surface of synovial cells and immune cells, competitively occupying the receptor's active binding sites. This action prevents endogenous bradykinin from binding to the B₂ receptor, thereby blocking bradykinin-mediated inflammatory signaling at its source.
Unlike bradykinin, when Icatibant binds to the B₂ receptor, it merely occupies the active site without inducing the conformational change necessary to trigger signal transduction. Consequently, it fails to activate key downstream signaling enzymes such as PLC and AC, and does not induce the release of pro-inflammatory cytokines or abnormal increases in vascular permeability. This specific blockade effect directly inhibits the amplification of the local inflammatory cascade in the joints, alleviates inflammatory edema and inflammatory infiltration in synovial tissue, and thereby relieves core clinical symptoms in RA patients, such as joint pain, swelling, and limited mobility.
Furthermore, the binding of Icatibant to the B₂ receptor is characterized by rapid reversibility. It is primarily excreted rapidly via the kidneys, has a short half-life in the body, and does not accumulate long-term in the joints or systemically. This property helps avoid interference with normal physiological regulatory functions (such as vascular tone regulation and local immune defense) during long-term use, thereby providing a safety assurance for its potential application in the long-term adjunctive treatment of RA.
Currently, research on it for rheumatoid arthritis (RA) primarily focuses on the preclinical and early clinical trial stages. Preliminary findings from these studies have provided initial evidence supporting its efficacy and safety in RA intervention.
In preclinical research, validation using RA animal models has shown that following this drug intervention, local bradykinin levels in the joints of model animals significantly decrease, the expression of pro-inflammatory cytokines is markedly reduced, synovial inflammatory edema is effectively alleviated, and joint tissue damage shows some degree of improvement.
In early clinical trials, small cohorts of RA patients receiving Icatibant peptide as an adjunctive treatment exhibited significant reductions in joint pain and swelling scores, along with varying degrees of improvement in inflammatory markers (such as erythrocyte sedimentation rate and C-reactive protein). Notably, no significant severe adverse reactions were observed, indicating a favorable safety profile.
Hot Tags: icatibant peptide, China icatibant peptide manufacturers, suppliers, Botulinum Toxin Injection 100iu, Nad Capsule, Nad Peptide Injection, Nad Tablet, BPC 157 Peptide Cream, BPC 157 Peptide Capsules
